This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Cigna (CI) Keep the Beat Streak Alive in Q2 Earnings?
by Zacks Equity Research
Cigna's (CI) business is likely to have been weighed down in Q2 due to high unemployment rate, partly offset by the delay in elective procedures resulting in lower claims.
Centene's (CNC) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Centene's (CNC) second-quarter results reflect robust revenues.
5 Healthcare Stocks to Beat on Q2 Earnings Despite Coronavirus
by Zacks Equity Research
Companies across the healthcare sector experience a mixed impact from coronavirus. While some gain traction from a surge in virtual care, the rest suffers demand woes and supply-chain glitches.
Anthem (ANTM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Anthem's (ANTM) second-quarter results are likely to reflect impressive revenues and rising membership.
What's in the Cards for Centene's (CNC) Q2 Earnings?
by Zacks Equity Research
Centene's (CNC) Q2 results are likely to reflect better revenues, partly offset by the COVID-19 impact.
Universal Health (UHS) to Report Q2 Earnings: What to Expect
by Zacks Equity Research
Universal Health's (UHS) second-quarter results are likely to reflect muted revenues.
Molina (MOH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Molina (MOH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HCA Healthcare's (HCA) Q2 Earnings Beat Estimates, Fall Y/Y
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter results reflect lower expenses, partly offset by a decline in admissions.
Should Value Investors Buy Molina (MOH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Molina Healthcare's Buyout Deal to Boost Its Base in Kentucky
by Zacks Equity Research
Molina Healthcare's (MOH) upcoming acquisition will fortify its presence in the Kentucky market.
Humana Ties Up With DCI's Affiliate to Serve Members With CKD
by Zacks Equity Research
Humana (HUM) ties up with DCI and its affiliate REACH Kidney Care to offer improved health outcomes for CKD patients in Alabama, North Carolina, South Carolina, and Tennessee.
Quest Diagnostics (DGX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
UnitedHealth's Unit Ties Up With Boulder Community Health
by Zacks Equity Research
UnitedHealth's (UNH) Optum reaches an agreement with Boulder Community Health to provide better medical services to communities in the Boulder County as well as its surroundings.
Why You Should Add Molina Healthcare (MOH) to Your Portfolio
by Zacks Equity Research
Riding high on its strategic initiatives and a solid top line, Molina Healthcare (MOH) holds enough potential to reap benefits for investors.
UnitedHealth's (UNH) Earnings in Q2 Beat on Lower Payouts
by Zacks Equity Research
UnitedHealth's (UNH) Q2 earnings outperformance is driven by a temporary postponement of care in the company's risk-based businesses amid the plaguing pandemic .
6 Health Insurance Stocks Poised to Beat on Earnings in Q2
by Sapna Bagaria
Health insurers' second-quarter 2020 earnings results are likely to gain from lower healthcare utilization, partly offset by higher costs.
Q2 Earnings Likely To Plunge: Invest in These Sector ETFs
by Sweta Killa
Earnings growth is expected to be negative for 15 of the 16 Zacks sectors with double-digit declines.
3 Health Insurers Poised for a Bull Run in the Second Half
by Srijita Guha
We shortlist three health insurance stocks for the second half of 2020 that should enhance your portfolio, given their solid fundamentals.
5 Reasons That Make Cigna (CI) an Attractive Stock to Own
by Zacks Equity Research
Acquisitions, business streamlining, strong balance sheet, high profitability, clear visibility of earnings growth make Cigna (CI) and attractive bet.
Is Molina Healthcare (MOH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (MOH) Outperforming Other Medical Stocks This Year?
Molina Healthcare (MOH) Acquires to Boost Medicaid Business
by Zacks Equity Research
Molina Healthcare (MOH) buys certain assets of YourCare Health Plan to enrich its portfolio and perk up its Medicaid business.
Is Molina (MOH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Humana's Testing Initiative to Aid Members Amid Coronavirus
by Zacks Equity Research
Humana (HUM) collaborates with Walmart, Quest, LabCorp for COVID-19 testing.
Cigna, Oscar to Launch Health Plan for Small Businesses
by Zacks Equity Research
Cigna (CI) along with Oscar unveils markets for Cigna + Oscar, aimed at aiding small businesses.
UnitedHealthcare'sTeledentistry Launch to Boost Oral Health
by Zacks Equity Research
UnitedHealth Group's (UNH) business - UnitedHealthcare - provides access to teledentistry option for its members in a bid to solve their oral health issues virtually.